Specific demographic, clinical, and financial characteristics are associated with glucagon-like peptide 1 (GLP-1) receptor ...

The centrally acting alpha2-adrenergic agonist allows for nighttime dosing and can be used with stimulants, the drug's ...

The number of adolescents and young adults prescribed a glucagon-like peptide-1 (GLP-1) receptor agonist increased nearly 600 ...

The number of young people in the US who are prescribed GLP-1 agonist drugs like Wegovy and Ozempic for weight loss and ...

For adolescents and young adults, glucagon-like peptide-1 receptor agonist (GLP-1 RA) dispensing increased from 2020 to 2023.

Zealand Pharma’s GLP-1/GLP-2 receptor dual agonist may have only managed at best an average 4.3% reduction in weight loss ...

Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of incretin mimetic medicines for the treatment of Type 2 ...

Patients who received CT-388 had an average placebo-adjusted weight loss of 18.8%. CT-388 is well tolerated with only mild to ...

The cannabinoid CB1 receptor inverse agonist INV-202 (monlunabant) is in clinical studies at Inversago Pharma Inc. as a potentially first-in-class drug for metabolic disorders, including diabetic ...

While Eli Lilly and Novo Nordisk currently dominate the GLP-1 receptor agonist space, there are more than 50 candidates in ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced positive results from the Phase Ib ...

ANV600 combines a non-blocking αPD-1 antibody and an IL-2Rβ/γ selective agonist targeting IL-2 to tumor-specific T cells resulting in ...